Duchenne Research Fund
  • Home
  • Duchenne facts
  • Our story
  • Our projects
  • News
  • Get involved
    • Get involved
    • Gallery
  • Contact
  • Donate
Select Page

ReveraGen receives $3.3m NIH grant for Vamorolone

18 Nov 2020

ReveraGen BioPharma has received a $3.3 million grant from the NIH – the US National Institutes of Health – for their ongoing work on the steroid alternative treatment Vamorolone for Duchenne muscular dystrophy. The NIH Commercialization Readiness Pilot...

Most recent:

  • FDA approves first gene therapy for Duchenne
  • DRF highlights psychosocial research at parent information day
  • See the smart suit that is changing children’s lives
  • DRF co-founder raises £15,000 in first marathon
  • DRF-funded KineDMD study published in Nature Medicine and featured on BBC

More about our projects:

administrative post award clinical post complementary current drug development early stage facility gene therapy past post project research standards of care

Jump to:

  • Donate
  • Contact Us
  • Get involved
  • Gallery
  • Our projects
  • Our story
  • Privacy
  • Home
  • Donate
  • Contact Us
  • Get involved
  • Gallery
  • Our projects
  • Our story
  • Privacy
  • Home
  • Facebook
  • Twitter
  • Instagram
Copyright © 2023 The Duchenne Research Fund. Registered Charity No. 1119068. Website by Sheli Rodney